Equities Analysts Issue Forecasts for HURA FY2025 Earnings

TuHURA Biosciences (NASDAQ:HURA) – Stock analysts at HC Wainwright issued their FY2025 earnings per share (EPS) estimates for TuHURA Biosciences in a research report issued on Friday, May 16th. HC Wainwright analyst R. Burns anticipates that the company will post earnings per share of ($0.56) for the year. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. HC Wainwright also issued estimates for TuHURA Biosciences’ FY2026 earnings at ($0.52) EPS.

TuHURA Biosciences Price Performance

Shares of HURA opened at $3.72 on Monday. TuHURA Biosciences has a 1 year low of $1.80 and a 1 year high of $7.93. The company’s 50 day simple moving average is $3.75 and its 200 day simple moving average is $4.07.

TuHURA Biosciences (NASDAQ:HURA) last posted its earnings results on Thursday, May 15th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02).

Hedge Funds Weigh In On TuHURA Biosciences

A number of large investors have recently bought and sold shares of HURA. Accent Capital Management LLC acquired a new position in shares of TuHURA Biosciences during the 4th quarter valued at $29,000. TT Capital Management LLC bought a new position in shares of TuHURA Biosciences in the fourth quarter worth $41,000. Jefferies Financial Group Inc. acquired a new stake in TuHURA Biosciences in the fourth quarter worth approximately $54,000. Bank of America Corp DE acquired a new stake in TuHURA Biosciences in the 4th quarter valued at about $59,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in shares of TuHURA Biosciences during the 4th quarter valued at $61,000. Hedge funds and other institutional investors own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.